Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)

Johann S. De Bono; Benjamin Garmezy; Dingwei Ye; Josep M. Piulats; Shahneen Sandhu; Andrew Ohyama Parsonson; Andrew James Weickhardt; Alok Tewari; Alison Helen Reid; Biao Song; Jiawei Wei; Peggy Wu; Hua Mu; Lara Ulrich; Evren Kocabas Argon; Aurora OBrate; Michael Pinho; Shanjun Helian; Raoul Tibes; Mark N. Stein

doi:10.1200/JCO.2026.44.16_suppl.TPS5137

Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)

Johann S. De Bono, Benjamin Garmezy, Dingwei Ye, Josep M. Piulats, Shahneen Sandhu, Andrew Ohyama Parsonson, Andrew James Weickhardt, Alok Tewari, Alison Helen Reid, Biao Song, Jiawei Wei, Peggy Wu, Hua Mu, Lara Ulrich, Evren Kocabas Argon, Aurora OBrate, Michael Pinho, Shanjun Helian, Raoul Tibes, Mark N. Stein

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	Bnt324-03
Pages (from-to)	TPS5137
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	44
Issue number	16 Supplement
DOIs	https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS5137
Publication status	Published - 1 Jun 2026
Event	2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, United States Duration: 29 May 2026 → 2 Jun 2026

Access to Document

10.1200/JCO.2026.44.16_suppl.TPS5137

Cite this

De Bono, J. S., Garmezy, B., Ye, D., Piulats, J. M., Sandhu, S., Parsonson, A. O., Weickhardt, A. J., Tewari, A., Reid, A. H., Song, B., Wei, J., Wu, P., Mu, H., Ulrich, L., Argon, E. K., OBrate, A., Pinho, M., Helian, S., Tibes, R., & Stein, M. N. (2026). Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 44(16 Supplement), TPS5137. Article Bnt324-03. https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS5137

@article{dc17a10279414c01873d3aa592dc207f,

title = "Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-na{\"i}ve metastatic castration-resistant prostate cancer (mCRPC)",

author = "\{De Bono\}, \{Johann S.\} and Benjamin Garmezy and Dingwei Ye and Piulats, \{Josep M.\} and Shahneen Sandhu and Parsonson, \{Andrew Ohyama\} and Weickhardt, \{Andrew James\} and Alok Tewari and Reid, \{Alison Helen\} and Biao Song and Jiawei Wei and Peggy Wu and Hua Mu and Lara Ulrich and Argon, \{Evren Kocabas\} and Aurora OBrate and Michael Pinho and Shanjun Helian and Raoul Tibes and Stein, \{Mark N.\}",

year = "2026",

month = jun,

day = "1",

doi = "10.1200/JCO.2026.44.16\_suppl.TPS5137",

language = "English",

volume = "44",

pages = "TPS5137",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "16 Supplement",

note = "2026 American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 29-05-2026 Through 02-06-2026",

}

De Bono, JS, Garmezy, B, Ye, D, Piulats, JM, Sandhu, S, Parsonson, AO, Weickhardt, AJ, Tewari, A, Reid, AH, Song, B, Wei, J, Wu, P, Mu, H, Ulrich, L, Argon, EK, OBrate, A, Pinho, M, Helian, S, Tibes, R & Stein, MN 2026, 'Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)', Journal of Clinical Oncology, vol. 44, no. 16 Supplement, Bnt324-03, pp. TPS5137. https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS5137

Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC). / De Bono, Johann S.; Garmezy, Benjamin; Ye, Dingwei et al.
In: Journal of Clinical Oncology, Vol. 44, No. 16 Supplement, Bnt324-03, 01.06.2026, p. TPS5137.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)

AU - De Bono, Johann S.

AU - Garmezy, Benjamin

AU - Ye, Dingwei

AU - Piulats, Josep M.

AU - Sandhu, Shahneen

AU - Parsonson, Andrew Ohyama

AU - Weickhardt, Andrew James

AU - Tewari, Alok

AU - Reid, Alison Helen

AU - Song, Biao

AU - Wei, Jiawei

AU - Wu, Peggy

AU - Mu, Hua

AU - Ulrich, Lara

AU - Argon, Evren Kocabas

AU - OBrate, Aurora

AU - Pinho, Michael

AU - Helian, Shanjun

AU - Tibes, Raoul

AU - Stein, Mark N.

PY - 2026/6/1

Y1 - 2026/6/1

U2 - 10.1200/JCO.2026.44.16_suppl.TPS5137

DO - 10.1200/JCO.2026.44.16_suppl.TPS5137

M3 - Meeting abstract

SN - 1527-7755

VL - 44

SP - TPS5137

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16 Supplement

M1 - Bnt324-03

T2 - 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Y2 - 29 May 2026 through 2 June 2026

ER -